Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918640 · ClinicalTrials.gov registry record · Phase 1
Lurbinectedin in FET-Fused Tumors
A Phase 1 study of Pediatric Cancer and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 6
- Study locations
NCT05918640: Recruiting Phase 1 study of Pediatric Cancer and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
NCT05918640 is a Phase 1 study of Pediatric Cancer and Ewing Sarcoma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 63 participants, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918640, a Phase 1 study of Pediatric Cancer and Ewing Sarcoma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Primary Outcome
First cycle (approximately 21 days) Dose Limiting Toxicities (DLTs) will be evaluated.
Conditions Studied
Interventions
- DRUG Lurbinectedin
Study Locations (6)
California
- Cedars-Sinai Medical Center - Los Angeles
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2028-07-30 |
| Phase | Phase 1 |
What NCT05918640 shows while recruiting
NCT05918640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lurbinectedin is the first listed.
NCT05918640 lists 6 locations in 6 states (California, Iowa, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05918640 about?
NCT05918640 is a clinical study titled "Lurbinectedin in FET-Fused Tumors". The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
What is the current status of trial NCT05918640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-07-27. Estimated completion is 2028-07-30.
What conditions does trial NCT05918640 study?
This clinical trial studies the following conditions: Pediatric Cancer, Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Undifferentiated Sarcoma.
What interventions are being tested in trial NCT05918640?
The interventions under investigation include: Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05918640?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918640 being conducted?
This trial has 6 study locations across California, Iowa, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918640's enrollment target sits among peer trials
63 25th of 51 higher than 27 of 51 other Pediatric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pediatric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
COMPLETED · Phase 1
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI